San Diego Companies Find Deals and Dollars at Health Conference
Summary
“The goal and vision have always been to develop a disruptive sequencing technology taking into account accuracy, speed, throughput and cost.” Human Longevity — a La Jolla company that strives to make medicine more predictive — on Jan. 10 sold its oncology division to Florida-based NeoGenomics for $37 million. Human Longevity says it assesses current and future health risks, drawing upon genome sequencing, lab tests, artificial intelligence and machine learning. “The acquisition enables Human Longevity to provide a complete health intelligence solution for our clients from early disease detection to personalized treatment,” Karow said. Human Longevity in early 2017 was valued at $1.6 billion, but nearly two years later received a $300 million valuation amid struggles to expand beyond its La Jolla testing site. Daré received an upfront payment for an undisclosed amount, and if the U.S. Food and Drug Administration approves the product, Bayer could pay an additional $20 million for exclusive commercialization rights.
Classifications
AskAI Classifications
LabelsLinked Companies
